Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 8, 2012, Pages 810-817

  Tennis, Patricia ^a   Rothman, Kenneth J ^a   Bohn, Rhonda L ^b   Tan, Hiangkiat ^b   Zavras, Athanasios ^c   Laskarides, Constantinos ^d   Calingaert, Brian ^a   Anthony, Mary S ^e  

^a RTI HEALTH SOLUTIONS   (United States)

^b HEALTHCORE INC   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d TUFTS UNIVERSITY   (United States)

^e AMGEN INC   (United States)

Author keywords

Bisphosphonates; Cancer; Osteonecrosis; Osteoporosis; Pharmacoepidemiology

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BREAST CANCER; COHORT ANALYSIS; FEMALE; HEALTH INSURANCE; HUMAN; INSURANCE; JAW OSTEONECROSIS; MALE; MORBIDITY; MULTIPLE MYELOMA; NEOPLASM; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY;

ADULT; AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BREAST NEOPLASMS; DIPHOSPHONATES; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84864345823     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3292     Document Type: Article

References (17)

1. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. J Oral Maxillofac Surg 2009; 67(5 Suppl): 2-12.
2. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis\osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-1575.
3. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83-93.
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
5. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J Am Dent Assoc 2008; 139: 23-30.
6. Wilkinson GS, Kuo YF, Freeman JL, et al. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007; 99: 1016-1024.
7. Zavras A, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006; 64: 917-923.
8. Harvard College. The public health disparities geocoding project monograph. Analytic methods. Harvard School of Public Health: Boston, MA, 2004. (accessed 6 March 2012).
9. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 1322.
10. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95: 1555-1565.
11. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27: 5356-5362.
12. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65: 1328-1331.
13. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968-971.
14. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-836.
15. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-1491.
16. Zavras AI. The impact of bisphosphonates on oral health: lessons from the past and opportunities for the future. Ann N Y Acad Sci 2011; 1218: 55-61.
17. Vis M, Bultink IE, Dijkmans BA, et al. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. Osteoporos Int 2005; 16: 1432-1435.